Last month (May 2025), Novo Nordisk and Septerna, a San Francisco, California-based bio/pharmaceutical company focused on GCPRs, formed an exclusive global collaboration and license agreement to discover, develop, and commercialize oral small-molecule medicines for treating obesity, Type 2 diabetes, and other cardiometabolic diseases, in a deal worth up to $2.2 billion ($200 million upfront and near-term funding and $2 billion in milestone payments)
What Makes Up MEDVi Are They Safe & Effective
Retatrutide is the newest GLP-1, GIP, and glucagon receptor agonist (GLP-1/GIP/GCG)a triple agonist designed to improve metabolic function and fat burning
But on the flip side, most everyone has felt that same disappointing feeling: stepping onto a scale expecting a loss, only to see that youve remained stagnant, or even gained weight
The same lifestyle that once maintained their weight no longer works because the hormonal machinery has changed